Review on the effectiveness and safety of biologic treatments versus steroids in the prevention of neurological complications in Behçet's disease
DOI:
https://doi.org/10.61182/rnavmed.v9n1a1Keywords:
Behçet's syndrome, Biological therapy, Methylprednisolone, Steroids, Effectiveness of treatmentAbstract
Behçet's syndrome, or Behçet's disease, is distinguished by the recurrent occurrence of oral thrush and various systemic manifestations, such as thrush in the genital area, eye problems, skin lesions, neurological symptoms, vascular disease and arthritis. Although its cause is unknown, it has been linked to certain genotypes and environmental factors of the patient. A systematic review of the literature was carried out in the MEDLINE, EMBASE, SCOPUS and Cochrane Library databases, without time or language restrictions. The search yielded 617 references. After elimination of duplicates and other criteria, 37 were reviewed in full-text. Three met the inclusion criteria. The use of 1 g of methylprednisolone in acute cases of NBD has shown that two thirds of patients with brainstem or brain lesions have a good recovery after treatment with this corticosteroid. Given the high incidence of vital organ involvement, extensive and consistent monitoring of appropriate treatment for Behçet's disease is essential. The limited evidence available to guide decisions on the use of corticosteroids and biologic therapies, which decrease disease progression and relapses, highlights the importance of conducting randomized controlled trials that provide stronger evidence on their safety and treatment regimens.
References
Yazici Y, Hatemi G, Bodaghi B, Cheon JH, Suzuki N, Ambrose N, et al. Behçet syndrome. Nat Rev Dis Prim 2021;7:67. https://doi.org/10.1038/s41572-021-00301-1
Ahn JK, Lee YS, Jeon CH, Koh E-M, Cha H-S. Treatment of venous thrombosis associated with Behcet’s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 2008;27:201–5. https://doi.org/10.1007/s10067-007-0685-z
Sanchis MN, Lluch E, Nijs J, Struyf F, Kangasperko M. The role of central sensitization in shoulder pain: A systematic literature review. Semin Arthritis Rheum 2015;44:710–6. https://doi.org/10.1016/j.semarthrit.2014.11.002
Al-Araji A, Kidd DP. Neuro-Behçet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol 2009;8:192–204. https://doi.org/10.1016/S1474-4422(09)70015-8
Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A, Constantinescu CS, et al. Diagnosis and management of Neuro-Behçet’s disease: international consensus recommendations. J Neurol 2014;261:1662–76. https://doi.org/10.1007/s00415-013-7209-3
Akiyama M, Kaneko Y, Takeuchi T. Effectiveness of tocilizumab in Behcet’s disease: A systematic literature review. Semin Arthritis Rheum 2020;50:797–804. https://doi.org/https://doi.org/10.1016/j.semarthrit.2020.05.017
Noel N, Bernard R, Wechsler B, Resche-Rigon M, Depaz R, Le Thi Huong Boutin D, et al. Long-term outcome of neuro-Behçet’s disease. Arthritis Rheumatol (Hoboken, NJ) 2014;66:1306–14. https://doi.org/10.1002/art.38351
Chajek T, Fainaru M. Behçet’s disease. report of 41 cases and a review of the literature. Medicine (Baltimore) 1975;54. https://doi.org/10.1097/00005792-197505000-00001
Yao M, Gao C, Zhang C, Di X, Liang W, Sun W, et al. Behcet’s disease with peripheral nervous system involvement successfully treated with golimumab: a case report and review of the literature. Rheumatol Int 2021;41:197–203. https://doi.org/10.1007/s00296-020-04650-0
Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, et al. Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet’s disease. J Neurol Sci 2015;349:143–8. https://doi.org/10.1016/j.jns.2015.01.005
Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703–12. https://doi.org/10.1056/NEJMoa035162
Miranda Rosero HA, Osorio S, Giraldo Méndez DP, Duque Botero J, Cataño JU, Tobón LI, et al. Tiempo en rango terapéutico (TRT) en clínica de anticoagulación: Reportes de eventos adversos y factores asociados a bajo TRT. Acta Médica Colomb 2016;41:42–8. https://doi.org/10.36104/amc.2016.524
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Oscar Iván Cujiño-Ibarra, Carlos Hernán Calderón Franco, Tatiana Andrea López-Areiza, Jonathan Alexander Guezguan-Pérez
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
